RxDoctor Payments Data

Pedro Yapor, MD

Internal Medicine · San Juan, PRNPI 1407930084

Payments from drug & device makers

$4,164in general payments, 2019–2025

Across 76 payments — averaging $54.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$3K
  • GSK$386
  • Boehringer Ingelheim$282
  • Merck$239
  • AstraZeneca$170
  • Bayer Puerto Rico Inc.$170
  • plus $213 from 4 others

What the payments were for

  • Consulting fees$2,21053%
  • Travel & lodging$1905%
  • Food & beverage$1,65540%
  • Education$1093%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,164 in reported general payments places this provider in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$19,511
Medicare patients
52
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat566$7,822,440
Trelegy ElliptaFluticasone/Umeclidin/Vilanter353$234,315
Breztri AerosphereBudesonide/Glycopyr/Formoterol312$210,930
Stiolto RespimatTiotropium Br/Olodaterol Hcl156$76,144
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate254$68,876
SymbicortBudesonide/Formoterol Fumarate86$21,005
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$18,727
Breo ElliptaFluticasone/Vilanterol36$15,527
Atrovent HfaIpratropium Bromide16$7,618
Clonazepam1,119$7,333
Mirtazapine298$4,108
Albuterol Sulfate HfaAlbuterol Sulfate79$3,365
Temazepam283$2,458
Fluticasone Propionate150$2,309
Trazodone Hcl293$2,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$2,705$7,822,440566 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$386$268,568428 claims
AstraZenecaBreztri Aerosphere, Symbicort$170$231,935398 claims
Boehringer IngelheimStiolto Respimat$282$76,144156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →